Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
Alnylam Pharmaceuticals (ALNY) PT Lowered to $116 at Evercore ISI
May 4, 2018 7:51 AM EDTEvercore ISI lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $116.00 (from $118.00) while maintaining a In Line rating.
... MoreAlnylam Pharma (ALNY) Posts Smaller-than-Expected Q1 Loss
May 3, 2018 4:01 PM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.22), $0.25 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $30.15 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More